Hannu Haapasalo

List of Publications by Year
in descending order

63	2,751	186265 28	182427 51
papers	citations	h-index	g-index

64	64	64	4743
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Method for the Intraoperative Detection of IDH Mutation in Gliomas with Differential Mobility Spectrometry. Current Oncology, 2022, 29, 3252-3258.	2.2	2
2	PATH-11. Detection of genetic and epigenetic alterations in Liquid Biopsies from pediatric brain tumor patients. Neuro-Oncology, 2022, 24, i160-i161.	1.2	0
3	CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity. JCI Insight, 2021, 6, .	5.0	23
4	Prostateâ€specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination toÂthe brain. Journal of Cellular and Molecular Medicine, 2020, 24, 6916-6927.	3.6	12
5	MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells. Cancers, 2020, 12, 654.	3.7	5
6	The Expression of Carbonic Anhydrases II, IX and XII in Brain Tumors. Cancers, 2020, 12, 1723.	3.7	26
7	Malignant Tumors of the Central Nervous System. , 2020, , 507-524.		0
8	Identifying brain tumors by differential mobility spectrometry analysis of diathermy smoke. Journal of Neurosurgery, 2020, 133, 100-106.	1.6	6
9	Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Histology and Histopathology, 2020, 35, 673-680.	0.7	3
10	Incidence trends of adult malignant brain tumors in Finland, 1990â€“2016. Acta OncolÃ³gica, 2019, 58, 990-996.	1.8	11
11	Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Journal of Physical Education and Sports Management, 2018, 4, a002246.	1.2	5
12	Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease. Annals of Diagnostic Pathology, 2018, 35, 80-84.	1.3	1
13	Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. BMC Cancer, 2017, 17, 310.	2.6	17
14	OUP accepted manuscript. Neuro-Oncology, 2017, 19, 1206-1216.	1.2	17
15	PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells. Cancer Research, 2016, 76, 7001-7011.	0.9	41
16	Diagnostically important muscle pathology in DNAJB6 mutated LGMD1D. Acta Neuropathologica Communications, 2016, 4, 9.	5.2	39
17	PROX1 is involved in progression of rectal neuroendocrine tumors, NETs. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 279-284.	2.8	12
18	Twist predicts poor outcome of patients with astrocytic glioma. Journal of Clinical Pathology, 2015, 68, 905-912.	2.0	17

#	Article	IF	Citations
19	PFKMgene defect and glycogen storage disease GSDVII with misleading enzyme histochemistry. Neurology: Genetics, 2015, 1, e7.	1.9	11
20	Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene, 2015, 34, 1619-1628.	5.9	82
21	Cyclin A predicts metastatic potential of rectal neuroendocrine tumors. Human Pathology, 2014, 45, 1605-1609.	2.0	6
22	Carbonic Anhydrase IX in Adult and Pediatric Brain Tumors. , 2013, , .		4
23	The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. Journal of Clinical Investigation, 2013, 123, 855-65.	8.2	159
24	Upstream Transcription Factor 1 (USF1) Polymorphisms Associate with Alzheimer's Diseaseâ€related Neuropathological Lesions: Tampere Autopsy Study. Brain Pathology, 2012, 22, 765-775.	4.1	17
25	Neurological outcome of childhood brain tumor survivors. Journal of Neuro-Oncology, 2012, 108, 153-161.	2.9	43
26	Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression. Journal of Neuro-Oncology, 2012, 108, 435-441.	2.9	17
27	Brain phenotype of carbonic anhydrase IX-deficient mice. Transgenic Research, 2012, 21, 163-176.	2.4	26
28	Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2. Acta Neuropathologica, 2010, 119, 465-479.	7.7	63
29	Novel myosin heavy chain immunohistochemical double staining developed for the routine diagnostic separation of I, IIA and IIX fibers. Acta Neuropathologica, 2010, 119, 495-500.	7.7	28
30	Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors. Journal of Neuro-Oncology, 2010, 97, 217-224.	2.9	38
31	Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors. BMC Cancer, 2010, 10, 104.	2.6	23
32	The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC Cancer, 2010, 10, 148.	2.6	71
33	Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication. BMC Cancer, 2010, 10, 181.	2.6	24
34	Mutant (CCTG)n Expansion Causes Abnormal Expression of Zinc Finger Protein 9 (ZNF9) in Myotonic Dystrophy Type 2. American Journal of Pathology, 2010, 177, 3025-3036.	3.8	70
35	Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features. Journal of Neurosurgery, 2009, 111, 472-477.	1.6	20
36	PME-1 Protects Extracellular Signal-Regulated Kinase Pathway Activity from Protein Phosphatase 2Aâ€“Mediated Inactivation in Human Malignant Glioma. Cancer Research, 2009, 69, 2870-2877.	0.9	80

#	Article	IF	Citations
37	Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma. BMC Cancer, 2009, 9, 57.	2.6	28
38	Apolipoprotein Eâ€“dependent accumulation of Alzheimer diseaseâ€“related lesions begins in middle age. Annals of Neurology, 2009, 65, 650-657.	5.3	250
39	Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. Journal of Neuro-Oncology, 2009, 95, 49-60.	2.9	34
40	Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology, 2009, 29, 242-247.	1.2	41
41	XRCC1 and XRCC3 variants and risk of glioma and meningioma. Journal of Neuro-Oncology, 2008, 88, 135-142.	2.9	77
42	Decreased expression of antioxidant enzymes is associated with aggressive features in ependymomas. Journal of Neuro-Oncology, 2008, 90, 283-291.	2.9	6
43	KIT overexpression induces proliferation in astrocytes in an imatinibâ€responsive manner and associates with proliferation index in gliomas. International Journal of Cancer, 2008, 123, 793-800.	5.1	9
44	Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer, 2008, 8, 1.	2.6	192
45	Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. Neuro-Oncology, 2008, 10, 131-138.	1.2	81
46	Carbonic Anhydrase IX Is Highly Expressed in Hereditary Nonpolyposis Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1760-1766.	2.5	46
47	Incidence of gliomas by anatomic location. Neuro-Oncology, 2007, 9, 319-325.	1.2	250
48	Carbonic anhydrase II in the endothelium of glial tumors: A potential target for therapy. Neuro-Oncology, 2007, 9, 308-313.	1.2	58
49	Desmoplastic infantile ganglioglioma: novel aspects in clinical presentation and genetics. World Neurosurgery, 2007, 68, 304-308.	1.3	29
50	Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival. Journal of Neuro-Oncology, 2006, 77, 131-140.	2.9	26
51	Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. Journal of Neuro-Oncology, 2006, 80, 1-7.	2.9	116
52	Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathologica, 2006, 111, 238-246.	7.7	57
53	Molecular genetic analysis of the REST/NRSF gene in nervous system tumors. Acta Neuropathologica, 2006, 112, 483-490.	7.7	28
54	Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas. Modern Pathology, 2005, 18, 1599-1605.	5.5	27

#	Article	IF	Citations
55	Expression of Antioxidant Enzymes in Astrocytic Brain Tumors. Brain Pathology, 2003, 13, 155-164.	4.1	54
56	Cancer incidence in families with multiple glioma patients. International Journal of Cancer, 2002, 97, 819-822.	5.1	30
57	Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique. Journal of Neuro-Oncology, 2001, 55, 29-37.	2.9	27
58	Analysis of p53 tumor suppressor gene in families with multiple glioma patients. Journal of Neuro-Oncology, 2001, 55, 159-165.	2.9	27
59	Chromosome imbalances in familial gliomas detected by comparative genomic hybridization. Genes Chromosomes and Cancer, 2000, 29, 339-346.	2.8	22
60	Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy. Journal of Neuro-Oncology, 2000, 46, 71-80.	2.9	53
61	CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. Journal of Neuro-Oncology, 1999, 41, 205-211.	2.9	44
62	Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. Journal of Neurosurgery, 1997, 87, 610-614.	1.6	73
63	Proliferative Potential of Sporadic and Neurofibromatosis 2-Associated Schwannomas as Studied by MIB-1 (Ki-67) and PCNA Labeling. Journal of Neuropathology and Experimental Neurology, 1995, 54, 776-782.	1.7	31